Rheumatology

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. A Study to Enroll Patients of Rheumatic Diseases and First-degree Relatives in a Biobank

   Rochester, Minn.

   The purpose of this study is to enroll rheumatic disease patients and first-degree relatives in a biobank, and to follow them over time to assess health outcomes and collect additional specimens.

2. A Study to Evaluate the Safety of Bone Marrow-Derived Stem Cells for Interstitial Lung Disease in Patients with Connective Tissue Disorders

   Jacksonville, Fla.

   The purpose of this study is to assess the safety of mesenchymal stem cells in patients with Interstitial Lung Disease (ILD) associated with Connective Tissue Disorders (CTD).

3. A Study to Evaluate Utilizing MRI for Earlier Diagnosis of Rheumatoid Arthritis

   Rochester, Minn.

   The primary purpose of this study is to describe the utilization and findings on magnetic resonance imaging (MRI) of the hands and feet in patients with seronegative rheumatoid arthritis (RA) (based on the ACR 1987 or 2010 classification criteria) compared to the findings seen in patients with seropositive disease (RF or ACPA positive).

4. A Study to Explore B-cell Activity Factor Receptor in Hematologic Malignancies and Autoimmune Rheumatologic Disorders

   Jacksonville, Fla.

   The purposes of this study are to explore the therapeutic efficacy of BAFFR-CAR T cells in BAFFR-expressing B-cell hematologic malignancies including large B-cell, mantle cell and follicular lymphoma, chronic lymphocytic leukemia (CLL) and B-cell acute lymphoblastic leukemia (B-cell ALL) using primary tumor and/or patient derived xenograft models, and to explore the therapeutic efficacy of BAFFR-CAR T cells in autoimmune rheumatologic diseases including  systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis using primary samples and/or patient derived xenograft models.

    

5. The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach

   Rochester, Minn.

   This study is a multi-center randomized controlled trial to evaluate the effects of using low-dose prednisone as compared to stopping prednisone treatment entirely. Participants will be randomized 1:1 to taper their prednisone dose down to 5 mg/day or to 0 mg/day for the duration of the study (approximately six months) or until a study endpoint.

6. A Study to to Determine the Impact of a Mobile Health Application on Rheumatoid Arthritis Shared Decision Making

   Rochester, Minn.

   The primary objective of this study is to determine the impact of ArthritisPower™ integration into the clinical evaluation of patients with RA on the primary endpoint of clinical improvement as defined by the continuous change in the Clinical Disease Activity Index.

7. A Study to Evaluate the Effectiveness and Safety of Daratumumab to Treat Patients with Active Lupus Nephritis

   Rochester, Minn.

   The purpose of this study is to assess the effectiveness and safety of daratumumab in inducing complete or partial remission in patients with active class III or IV (± V) lupus nephritis (LN) as measured by change in proteinuria and serum creatinine.

    

    

    

8. The ANSWERS Study

   Rochester, Minn.

   The purpose of this study is to better understand Antiphospholipid syndrome (APS) pathophysiology and to aid development of targeted therapeutics.

9. A Study to Evaluate Cardiopulmonary Complications in Systemic Sclerosis

   Rochester, Minn.

   The purpose of this study is to assess whether our not the percentage of pulmonary related vascular structures (PRVS) determined by the quantitative CT (Q-CT) tool CALIPER is a novel measure that can be used for the early detection of pulmonary vascular remodeling in patients with SSc.  pulmonary related vascular structures

10. Biomarkers in Autoimmune and Inflammatory Diseases

    Rochester, Minn.

    The purpose of this study is to identify biomarkers in people with autoimmune or inflammatory disease and in healthy people. We will use these biomarkers to develop tests that will help us better understand the same biomarkers in the blood of people who have autoimmune and inflammatory diseases.